Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Non-Hodgkin 7Lymphoma, Mantle-Cell 6Hodgkin Disease 5Lymphoma, Large B-Cell, Diffuse 4Lymphoma, Follicular 4Lymphoma, T-Cell 3Lymphoma, B-Cell 3Leukemia, Lymphocytic, Chronic, B-Cell 3Gliosarcoma 3Glioblastoma 3Burkitt Lymphoma 3Multiple Myeloma 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma 2Leukemia, Prolymphocytic, T-Cell 2Glioma 2Waldenstrom Macroglobulinemia 1Sezary Syndrome 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Plasmablastic Lymphoma 1Pdgfra-Associated Chronic Eosinophilic Leukemia 1Neoplasms, Plasma Cell 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large-Cell, Anaplastic 1

Interventions

Cyclophosphamide 27fludarabine phosphate 19Whole-Body Irradiation 18Peripheral Blood Stem Cell Transplantation 18Etoposide 17Rituximab 15Brentuximab Vedotin 15Mycophenolic Acid 14Tacrolimus 13Doxorubicin 12Vincristine 11Prednisone 11Methotrexate 11Busulfan 11Melphalan 9Antilymphocyte Serum 9Cyclosporine 8Filgrastim 6Carboplatin 6Sirolimus 5Radiotherapy 5Lenalidomide 5Gene Expression Profiling 5Cytarabine 5merphos 4Vorinostat 4Immunohistochemistry 4Ifosfamide 4Gemcitabine 4Flow Cytometry 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Lymphoma, Large-Cell, Anaplastic × carmustine, poliferprosan 20 drug combination × Clear all
NCT01035463 2023-10-10

Lenalidomide Therapy After Chemotherapy & Stem Cell Transplant in Treating Chemotherapy Resistan Non-Hodgkin Lymphoma

University of Nebraska

Phase 1/2 Completed
74 enrolled 11 charts
Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡